Immuron Ltd
ANW
Company Profile
Business description
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Contact
Chapman Street
Unit 10, 25-37
Blackburn North
MelbourneVIC3130
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,203.90 | 28.80 | 0.35% |
| CAC 40 | 7,570.51 | 34.25 | 0.45% |
| DAX 40 | 22,256.79 | 14.34 | 0.06% |
| Dow JONES (US) | 40,093.38 | 20.12 | -0.05% |
| FTSE 100 | 8,422.04 | 6.79 | 0.08% |
| HKSE | 21,971.96 | 8.78 | -0.04% |
| NASDAQ | 17,206.66 | 176.28 | -1.01% |
| Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
| NZX 50 Index | 12,098.89 | 81.05 | 0.67% |
| S&P 500 | 5,495.70 | 29.51 | -0.53% |
| S&P/ASX 200 | 7,997.10 | 28.90 | 0.36% |
| SSE Composite Index | 3,288.41 | 6.65 | -0.20% |